InBiomics
InBiomics provides an AI-powered blood test that differentiates Major Depressive Disorder from Bipolar Disorder with 97.8% peer-reviewed accuracy, delivering results within 24 hours. The non-invasive liquid biopsy approach replaces subjective questionnaires and lengthy trial-and-error methods, helping clinicians make objective, data-driven diagnoses and avoid costly failed treatments.
- Artificial Intelligence
- Digital Health
- Healthcare Technology
- Software Only
Funding
Founders
Product
Problem
Distinguishing Major Depressive Disorder from Bipolar Disorder still relies on subjective assessments and costly trial-and-error methods, leading patients to endure up to 10 years of suffering before receiving an accurate diagnosis. Misdiagnosis can trigger medication-induced disorders and worsen outcomes, while failed interventions accumulate massive economic burdens for patients and healthcare systems.
Solution
InBiomics offers a blood-based diagnostic platform that leverages AI-powered analysis to objectively differentiate Major Depressive Disorder, Bipolar Disorder, and healthy controls. From a simple non-invasive blood draw, advanced algorithms process biological signals to deliver actionable clinical insights within 24 hours. The technology applies the same liquid biopsy approach that revolutionized oncology to mental health, replacing lengthy questionnaires and imaging with data-driven biological measurements. Peer-reviewed validation published in Nature Scientific Reports demonstrated 97.8% accuracy in classification, positioning the platform as a scalable tool for widespread clinical adoption.
Target Audience
Primary users are psychiatrists, primary care physicians, and mental health clinics seeking objective diagnostic tools for mood disorder differentiation, along with healthcare systems aiming to reduce misdiagnosis costs and improve treatment pathways.
Features
- AI-powered analysis of blood samples to classify MDD, Bipolar Disorder, and healthy controls with 97.8% accuracy (44/45 cases)
- Results delivered within 24 hours from a simple non-invasive blood draw
- Validated in a peer-reviewed study published in Nature Scientific Reports (2026)
- Pipeline expanding to chronic pain and other CNS conditions
- Designed for remote monitoring and treatment optimization across healthcare systems
- Scalable platform architecture suitable for widespread clinical integration